Mohamed Ahmed Allam, Risse Kathrin, Stock Jennifer, Heinzel Alexander, Mottaghy Felix M, Bruners Philipp, Eble Michael J
Department of Radiation Oncology, RWTH Aachen University Hospital, 52074 Aachen, Germany.
Center for Integrated Oncology Aachen, Bonn, Cologne and Duesseldorf (CIO ABCD), 52074 Aachen, Germany.
Cancers (Basel). 2022 Sep 18;14(18):4521. doi: 10.3390/cancers14184521.
Sarcopenia and body composition parameters such as visceral and subcutaneous adipose tissue and visceral-to-subcutaneous adipose tissue ratio have been shown to be relevant biomarkers for prognosis in patients with different types of cancer. However, these findings have not been well studied in anal cancer to date. Therefore, the aim of this study was to evaluate the prognostic value of different body composition parameters in patients undergoing radiation therapy for the treatment of anal cancer with curative intent. After approval by the institutional ethical committee, we retrospectively identified 81 patients in our local registry, who received radical intensity-modulated radiotherapy for the management of anal squamous cell cancer (ASCC). Clinical information, including body mass index (BMI), survival, and toxicities outcome, were retrieved from the local hospital registry. Based on the pre-therapeutic computer tomography (CT), we measured the total psoas muscle area, visceral adipose tissue area (VAT), subcutaneous adipose tissue area (SAT), and visceral-to-subcutaneous adipose tissue area ratio (VSR). In addition to the classical prognostic factors as T-stage, N-stage, gender, and treatment duration, we analyzed the impact of body composition on the prognosis in univariate and multivariate analyses. Sarcopenia was not associated with increased mortality in anal cancer patients, whereas increased BMI (≥27 kg/m) and VSR (≥0.45) were significantly associated with worsened overall survival and cancer-specific survival in both univariate and multivariate analyses. VSR-not BMI-was statistically higher in males. Sarcopenia and VSR ≥ 0.45 were associated with advanced T-stages. None of the body composition parameters resulted in a significant increase in treatment-related toxicities. : BMI and visceral adiposity are independent prognostic factors for the survival of patients with anal cancer. Measurements to treat adiposity at the time of diagnosis may be needed to improve the survival outcomes for the affected patients.
肌肉减少症以及身体成分参数,如内脏和皮下脂肪组织以及内脏与皮下脂肪组织比率,已被证明是不同类型癌症患者预后的相关生物标志物。然而,迄今为止,这些发现尚未在肛门癌中得到充分研究。因此,本研究的目的是评估不同身体成分参数对接受根治性放疗的肛门癌患者的预后价值。经机构伦理委员会批准后,我们在本地登记处回顾性确定了81例患者,他们接受了根治性调强放疗以治疗肛门鳞状细胞癌(ASCC)。从当地医院登记处检索了包括体重指数(BMI)、生存率和毒性结果在内的临床信息。基于治疗前的计算机断层扫描(CT),我们测量了腰大肌总面积、内脏脂肪组织面积(VAT)、皮下脂肪组织面积(SAT)以及内脏与皮下脂肪组织面积比(VSR)。除了T分期、N分期、性别和治疗持续时间等经典预后因素外,我们在单因素和多因素分析中分析了身体成分对预后的影响。肌肉减少症与肛门癌患者死亡率增加无关,而在单因素和多因素分析中,BMI增加(≥27 kg/m²)和VSR增加(≥0.45)均与总体生存率和癌症特异性生存率恶化显著相关。男性的VSR(而非BMI)在统计学上更高。肌肉减少症和VSR≥0.45与晚期T分期相关。没有任何身体成分参数导致治疗相关毒性显著增加。:BMI和内脏肥胖是肛门癌患者生存的独立预后因素。可能需要在诊断时采取措施治疗肥胖,以改善受影响患者的生存结果。